Skip to main content
. 2022 Jan 23;14(2):265. doi: 10.3390/pharmaceutics14020265

Figure 5.

Figure 5

Figure 5 illustrates the intravitreal drug concentration and free VEGF proportion in a patient treated with q8 (a), q10 (b), or q12 (c) 6 mg brolucizumab injections.